The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …

The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …

On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B. 1.1.
529 was announced, containing far more mutations in Spike (S) than previously reported …

Summary The SARS-CoV-2 Omicron variant with increased fitness is spreading rapidly
worldwide. Analysis of cryo-EM structures of the spike (S) from Omicron reveals amino acid …

Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone
progressive change, with variants conferring advantage rapidly becoming dominant …

Although most mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) genome are expected to be either deleterious and swiftly purged or relatively …

Background REGEN-COV (previously known as REGN-COV2), a combination of the
monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the …